The FDA has granted moderate complexity status for Meridian Bioscience's Group A and Group B Streptococcus tests under the agency's Clinical Laboratory Improvement Amendments program. The assays, which already have been cleared by the FDA and run on the company's illumigene platform, originally were classified as high complexity tests.

Related Summaries